{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T23:06:09Z","timestamp":1772319969760,"version":"3.50.1"},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,2,14]]},"DOI":"10.18632\/oncotarget.28195","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T13:45:35Z","timestamp":1644846335000},"page":"332-346","source":"Crossref","is-referenced-by-count":25,"title":["Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity"],"prefix":"10.18632","volume":"13","author":[{"given":"Daniel","family":"Menendez","sequence":"first","affiliation":[{"name":"Chromosomal Stability Group, Genome Integrity and Structural Biology Laboratory, NIEHS, NIH, Durham, NC 27709, USA"},{"name":"Environmental Cardiopulmonary Disease Group, Immunity, Inflammation and Disease Laboratory, NIEHS, NIH, Durham, NC 27709, USA"},{"name":"These authors contributed equally to this work"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay R.","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois, Rockford, IL 61107, USA"},{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"These authors contributed equally to this work"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carri C.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Chromosomal Stability Group, Genome Integrity and Structural Biology Laboratory, NIEHS, NIH, Durham, NC 27709, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney J.","family":"Bell","sequence":"additional","affiliation":[{"name":"Chromosomal Stability Group, Genome Integrity and Structural Biology Laboratory, NIEHS, NIH, Durham, NC 27709, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Fu","sequence":"additional","affiliation":[{"name":"Functional Genomics Laboratory, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Slepushkina","sequence":"additional","affiliation":[{"name":"Functional Genomics Laboratory, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Buehler","sequence":"additional","affiliation":[{"name":"Functional Genomics Laboratory, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott E.","family":"Martin","sequence":"additional","affiliation":[{"name":"Functional Genomics Laboratory, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Lal-Nag","sequence":"additional","affiliation":[{"name":"Functional Genomics Laboratory, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20850, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Nitiss","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois, Rockford, IL 61107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Resnick","sequence":"additional","affiliation":[{"name":"Chromosomal Stability Group, Genome Integrity and Structural Biology Laboratory, NIEHS, NIH, Durham, NC 27709, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1021\/cr900097c","article-title":"DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition","volume":"10","author":"Pommier","year":"2009","journal-title":"Chem Rev"},{"key":"2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev.bi.65.070196.003223","article-title":"DNA topoisomerases","volume":"6","author":"Wang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/carcin\/19.6.965","article-title":"Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase","volume":"1","author":"Weaver","year":"1998","journal-title":"Carcinogenesis"},{"key":"6","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1073\/pnas.85.20.7501","article-title":"DNA topoisomerase-targeting antitumor drugs can be studied in yeast","volume":"8","author":"Wang","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bcp.2015.12.015","article-title":"Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II","volume":"10","author":"Austin","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"8","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1126\/science.aam6468","article-title":"ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links","volume":"35","author":"Williams","year":"2017","journal-title":"Science"},{"key":"9","doi-asserted-by":"publisher","first-page":"102837","DOI":"10.1016\/j.dnarep.2020.102837","article-title":"Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC)","volume":"8","author":"Pommier","year":"2020","journal-title":"DNA Repair (Amst)"},{"key":"10","doi-asserted-by":"publisher","first-page":"e53447","DOI":"10.7554\/eLife.53447","article-title":"Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity","volume":"9","author":"Nussenzweig","year":"2020","journal-title":"Elife"},{"key":"11","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"17","author":"Lowe","year":"2017","journal-title":"Cell"},{"key":"12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrm1546","article-title":"p53: traffic cop at the crossroads of DNA repair and recombination","volume":"6","author":"Harris","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data","volume":"3","author":"Olivier","year":"2016","journal-title":"Hum Mutat"},{"key":"14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jmcb\/mjz067","article-title":"Gain-of-function mutant p53: history and speculation","volume":"1","author":"Prives","year":"2019","journal-title":"J Mol Cell Biol"},{"key":"15","first-page":"307","article-title":"Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents","volume":"8","author":"Brandner","year":"1993","journal-title":"Oncogene"},{"key":"16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"2","author":"Olivier","year":"2007","journal-title":"Hum Mutat"},{"key":"17","doi-asserted-by":"publisher","first-page":"eaba6290","DOI":"10.1126\/sciadv.aba6290","article-title":"A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation","volume":"6","author":"Pommier","year":"2020","journal-title":"Sci Adv"},{"key":"18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4939-7459-7_20","article-title":"Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells","volume":"170","author":"Nitiss","year":"2018","journal-title":"Methods Mol Biol"},{"key":"19","first-page":"976","article-title":"Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation: possible relationship with DNA repair","volume":"5","author":"Muller","year":"1998","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/1541-7786.MCR-17-0019","article-title":"The CytidineDeaminase APOBEC3 Family Is Subject to Transcriptional Regulation by p53","volume":"1","author":"Resnick","year":"2017","journal-title":"Mol Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"27030","DOI":"10.1074\/jbc.m402056200","article-title":"Stable suppression of the R2 subunit of ribonucleotidereductase by R2-targeted short interference RNA sensitizes p53(-\/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotidereductase inhibitors","volume":"27","author":"Sartorelli","year":"2004","journal-title":"J Biol Chem"},{"key":"22","doi-asserted-by":"publisher","first-page":"34956","DOI":"10.18632\/oncotarget.9008","article-title":"Identification of genes that are essential to restrict genome duplication to once per cell division","volume":"7","author":"DePamphilis","year":"2016","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","article-title":"STRING v10: protein-protein interaction networks, integrated over the tree of life","volume":"4","author":"von Mering","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapyantitumor activity","volume":"5","author":"Page","year":"2013","journal-title":"J Med Chem"},{"key":"25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1006\/bbrc.2001.6095","article-title":"Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM\/ATR","volume":"28","author":"Darbon","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrc3892","article-title":"Topoisomerase-mediated chromosomal break repair: an emerging player in many games","volume":"1","author":"El-Khamisy","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"26876","DOI":"10.1073\/pnas.2008721117","article-title":"Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast","volume":"11","author":"Nitiss","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"1","author":"Nitiss","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"29","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/acs.biochem.1c00240","article-title":"Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors","volume":"6","author":"Osheroff","year":"2021","journal-title":"Biochemistry"},{"key":"30","first-page":"2803","article-title":"Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions","volume":"2","author":"Ranzani","year":"2001","journal-title":"Anticancer Res"},{"key":"31","first-page":"4074","article-title":"G2 arrest in response to topoisomerase II inhibitors: the role of p53","volume":"6","author":"Taylor","year":"2003","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s1568-7864(02)00185-4","article-title":"Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling","volume":"2","author":"Kaina","year":"2003","journal-title":"DNA Repair (Amst)"},{"key":"33","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3892\/ijo.23.5.1431","article-title":"p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase","volume":"2","author":"Fink","year":"2003","journal-title":"Int J Oncol"},{"key":"34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/dna.2007.0578","article-title":"Absence of p53 enhances growth defects and etoposide sensitivity of human cells lacking the Bloom syndrome helicase BLM","volume":"2","author":"Koyama","year":"2007","journal-title":"DNA Cell Biol"},{"key":"35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/(sici)1097-4644(19991101)75:2<245::aid-jcb7>3.3.co;2-7","article-title":"Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines","volume":"7","author":"Sullivan","year":"1999","journal-title":"J Cell Biochem"},{"key":"36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1368-7646(02)00143-7","article-title":"Tumor p53 status and response to topoisomerase II inhibitors","volume":"6","author":"Sullivan","year":"2003","journal-title":"Drug Resist Updat"},{"key":"37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1128\/MCB.17.1.389","article-title":"Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor","volume":"1","author":"Suttle","year":"1997","journal-title":"Mol Cell Biol"},{"key":"38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1101\/gad.181685.111","article-title":"Mutant p53 cooperates with ETS2 to promote etoposide resistance","volume":"2","author":"Martinez","year":"2012","journal-title":"Genes Dev"},{"key":"39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1172\/JCI6863","article-title":"Disruption of p53 in human cancer cells alters the responses to therapeutic agents","volume":"10","author":"Vogelstein","year":"1999","journal-title":"J Clin Invest"},{"key":"40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10495-005-1898-8","article-title":"Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis","volume":"1","author":"Fang","year":"2005","journal-title":"Apoptosis"},{"key":"41","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/362849a0","article-title":"Thymocyte apoptosis induced by p53-dependent and independent pathways","volume":"36","author":"Wyllie","year":"1993","journal-title":"Nature"},{"key":"42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/sj.bjc.6604465","article-title":"Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine","volume":"9","author":"Klagsbrun","year":"2008","journal-title":"Br J Cancer"},{"key":"43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0092-8674(94)90201-1","article-title":"DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2","volume":"7","author":"Cory","year":"1994","journal-title":"Cell"},{"key":"44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00003088-200443070-00002","article-title":"Pharmacokinetic optimisation of treatment with oral etoposide","volume":"4","author":"Boiocchi","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"45","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cortez","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"46","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1074\/jbc.m106113200","article-title":"ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint","volume":"27","author":"Schreiber","year":"2002","journal-title":"J Biol Chem"},{"key":"47","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1535-7163.mct-06-0679","article-title":"Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival","volume":"6","author":"Bunz","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","article-title":"Targeting ATR in DNA damage response and cancer therapeutics","volume":"4","author":"Muschel","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"49","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/ng.441","article-title":"Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53","volume":"4","author":"Brown","year":"2009","journal-title":"Nat Genet"},{"key":"50","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs","volume":"5","author":"Fernandez-Capetillo","year":"2011","journal-title":"Mol Oncol"},{"key":"51","first-page":"36832","article-title":"ATR enforces the topoisomerase II-dependent G2 checkpoint through inhibition of Plk1 kinase","volume":"27","author":"Kaufmann","year":"2002","journal-title":"J Biol Chem"},{"key":"52","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ncb1828","article-title":"Topoisomerase IIalpha controls the decatenation checkpoint","volume":"1","author":"Lou","year":"2009","journal-title":"Nat Cell Biol"},{"key":"53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","article-title":"A Genetic Map of the Response to DNA Damage in Human Cells","volume":"18","author":"Moatti","year":"2020","journal-title":"Cell"},{"key":"54","doi-asserted-by":"publisher","first-page":"7286","DOI":"10.1093\/nar\/gkt504","article-title":"Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells","volume":"4","author":"Resnick","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1593\/neo.08120","article-title":"Different mutant\/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells","volume":"1","author":"Futscher","year":"2008","journal-title":"Neoplasia"},{"key":"56","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nmeth1089","article-title":"A probability-based approach for the analysis of large-scale RNAi screens","volume":"4","author":"Chanda","year":"2007","journal-title":"Nat Methods"},{"key":"57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1087057107312035","article-title":"Median absolute deviation to improve hit selection for genome-scale RNAi screens","volume":"1","author":"Strulovici","year":"2008","journal-title":"J Biomol Screen"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T13:45:44Z","timestamp":1644846344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2,14]]}},"alternative-id":["28195"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28195","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]}}}